Long-Term Follow-up of Subjects Who Were Treated With ST-920
NCT ID: NCT05039866
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
48 participants
OBSERVATIONAL
2021-08-16
2039-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
NCT04046224
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
NCT05710692
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
NCT04999059
Extension Study of PRX-102 for up to 60 Months
NCT01981720
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
NCT03566017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects who received ST-920
Subjects who received ST-920 in a separate parent trial
ST-920
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ST-920
No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who have consented to participate in this LTFU study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sangamo Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Sangamo Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Irvine
Irvine, California, United States
University of South Florida
Tampa, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Mt. Sinai Hospital
New York, New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Fairfax, Virginia, United States
The Royal Melbourne Hospital
Parkville, Victoria, Australia
M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, Canada
University Hospital of Würzburg
Würzburg, , Germany
Addenbrooke's Hospital
Cambridge, , United Kingdom
Royal Free Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ST-920-LT01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.